Vaccine candidates that have proved effective against MERSCoV
infections in in vitro culture conditions need to be evaluated in
effective animal challenge models to confirm protective immunity.
MERS-CoV has been shown to cause transient lower respiratory
tract infection in rhesus macaques, and infected monkeys demonstrated
clinical signs of diseases, virus replication, histological
lesions and neutralizing antibody generation